title: Chelation of thallium by combining deferasirox and desferrioxamine in rats.
abstract: The hypothesis that two known chelators deferasirox (4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid) and desferrioxamine (DFO) might be more efficient as combined treatment than as monotherapies in removing thallium from the body was tested in a new acute rat model. 7-week-old male Wistar rats received chelators: deferasirox (orally), DFO (intraperitoneal; i.p.), or deferasirox + DFO as 75 or 150 mg/kg dose half an hour after a single i.p. administration of 8 mg thallium/kg body weight in the form of chloride. Serum thallium concentration, urinary thallium, and iron excretions were determined by graphite furnace atomic absorption spectrometry. Both chelators were effective only at the higher dose level, while DFO was more effective than deferasirox in enhancing urinary thallium excretion, deferasirox was more effective than DFO in enhancing urinary iron excretion. In the combined treatment group, deferasirox did not increase the DFO effect on thallium and DFO did not increase the effect of deferasirox on iron elimination. Our results support the usefulness of this animal model for preliminary in vivo testing of thallium chelators. Urinary values were more useful because of the high variability of serum results.
authors.affiliation: Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Islamic Republic of Iran.
authors.forename: Amir Shokooh
authors.initials: AS
authors.lastname: Saljooghi
authors.affiliation: Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Islamic Republic of Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Babaie
authors.affiliation: Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Islamic Republic of Iran.
authors.forename: Fatemeh Delavar
authors.initials: FD
authors.lastname: Mendi
authors.affiliation: Department of Chemistry, Ferdowsi University of Mashhad, Mashhad, Islamic Republic of Iran.
authors.forename: Maliheh
authors.initials: M
authors.lastname: Zahmati
authors.affiliation: Department of Fisheries, Chabahar Maritime University, Chabahar, Islamic Republic of Iran amir.saljooghi@yahoo.com.
authors.forename: Zoheir Shokouh
authors.initials: ZS
authors.lastname: Saljooghi
mesh_terms: D000818:Animals; D001565:Benzoates / Q000737:chemistry / Q000494:pharmacology*; D015913:Chelation Therapy; D000077588:Deferasirox; D003676:Deferoxamine / Q000737:chemistry / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007501:Iron / Q000652:urine; D007502:Iron Chelating Agents / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013054:Spectrophotometry, Atomic; D013793:Thallium / Q000008:administration & dosage / Q000633:toxicity* / Q000652:urine; D014230:Triazoles / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D013793:Thallium; D007501:Iron; D003676:Deferoxamine; D000077588:Deferasirox
keywords: Deferasirox; desferrioxamine; iron; serum; thallium; urine